Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Stuart

Internal Medicine Shreveport, LA Medical Doctor

NPI 1508839788 CMS profile 158934

9320 Linwood Ave, Shreveport, LA 71106

Open in the dashboard

General payments

$3,757

263 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anthony Stuart of Shreveport, LA is reported in the CMS Open Payments database as having received $3,757 across 263 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $749 42
2024 General $735 45
2023 General $805 54
2022 General $241 15
2021 General $57 2
2020 General $117 9
2019 General $1,054 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Stuart
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Anthony Stuart were reported at $749. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Anthony Stuart Internal Medicine median Middle half National median
2019 $1,054 $159 $48–$570 $163
2020 $117 $119 $33–$402 $114
2021 $57 $135 $37–$521 $132
2022 $241 $141 $42–$496 $149
2023 $805 $149 $45–$519 $160
2024 $735 $154 $47–$537 $164
2025 $749 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $649 55 payments
  2. GlaxoSmithKline, LLC. $480 41 payments
  3. AstraZeneca Pharmaceuticals LP $353 17 payments
  4. Novo Nordisk Inc $262 16 payments
  5. Lilly USA, LLC $258 18 payments
  6. Janssen Pharmaceuticals, Inc $162 14 payments
  7. Merck Sharp & Dohme Corporation $160 12 payments
  8. Dexcom, Inc. $133 7 payments
  9. Allergan Inc. $110 13 payments
  10. AbbVie, Inc. $97 5 payments
  11. Other $1,092 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,679 260 payments
  2. Education $78 3 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS $421 30 payments
  2. NURTEC ODT $415 29 payments
  3. TRELEGY ELLIPTA $339 28 payments
  4. PAXLOVID $279 20 payments
  5. MOUNJARO $250 17 payments
  6. FARXIGA $177 6 payments
  7. XARELTO $157 13 payments
  8. CHANTIX $136 17 payments
  9. LOKELMA $134 3 payments
  10. Dexcom G6 Transmitter $133 7 payments
  11. Other $3,307 241 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 190 drugs

Part D claims

15,880

Median for Internal Medicine: 777

Drug cost

$1,467,905

Median for Internal Medicine: $73,373

Branded share of claims

20.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 221 $258,192
Ozempic Semaglutide Brand 133 $136,509
Eliquis Apixaban Brand 143 $135,157
Jardiance Empagliflozin Brand 87 $107,396
Januvia Sitagliptin Phosphate Brand 104 $104,285
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 112 $83,795
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 13 $51,756
Tresiba Flextouch U-100 Insulin Degludec Brand 48 $47,522
Farxiga Dapagliflozin Propanediol Brand 50 $45,339
Odefsey Emtricitab/Rilpiviri/Tenof Ala Brand 12 $42,609

The 10 drugs with the highest cost, of 190 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$581,136

Of which drugs: $23,182

Medicare patients

1,012

Average age 73

Services billed

9,203

531 women, 481 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 46%
Ischemic heart disease 43%
Chronic kidney disease 38%
Heart failure 35%
Depression 32%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 42 42 $12,166
Vaccine for influenza for injection into muscle 90662 Office 121 124 $10,027
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 18 18 $372
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 15 43 $240
Injection, ketorolac tromethamine, per 15 mg J1885 Office 13 46 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $71
$71 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $56
$56 112 —
ELIQUIS
  • PFIZER INC. $54
$54 143 —
NURTEC ODT
  • PFIZER INC. $54
$54 — —
PAXLOVID
  • PFIZER INC. $42
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record